Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: In vivo and in vitro studies

International Journal of Cardiology

Volumn 121, Issue 3, 2007, Pages 253-260

  Yip, Hon Kan ^a   Sun, Cheuk Kwan ^a   Chang, Li Teh ^b   Wu, Chiung Jen ^a   Chua, Sarah ^a   Fu, Morgan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

Author keywords

Cell adhesion molecules; Endothelial cells; High sensitivity C reactive protein; Simvastatin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; UMBILICAL VEIN;

ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; RISK FACTORS; SIMVASTATIN; UMBILICAL VEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 34548855945     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.035     Document Type: Article

References (18)

1. van der Wal A.C., Becker A.E., van der Loos C.M., and Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
2. Libby P., Geng Y.J., Sukhova G.K., Simon D.I., and Lee R.T. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci 811 (1997) 134-145
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
4. Pasceri V., Chang J., Willerson J.T., and Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cell by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
5. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-761
6. Burke A.P., Tracy R.P., Kologie F., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105 (2002) 2019-2023
7. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
8. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 105 (2002) 1412-1415
9. Verma S., Buchanan M.R., and Anderson T.J. Endothelial function testing as a biomarker of vascular disease. Circulation 108 (2003) 2054-2059
10. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 108 (2003) 1917-1923
11. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
12. van de Ree M.A., Huisman M.V., Princen H.M.G., Meinders A.E., and Kluft. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166 (2003) 129-135
13. Pai J.K., Pischon T., Ma J., et al. Inflammatory makers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
14. Bharadwaj D., Stein M.P., Volzer M., Mold C., and Du Clos T.W. The major receptor for C-reactive protein on leukocytes is fcγ receptor II. J Exp Med 190 (1999) 585-590
15. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
16. The Long-Term Intervention with Pravastatin in Ischemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
17. Rider P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
18. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38